直接抗丙肝药物联合治疗方案的研究进展  

Research progress on combination therapeutic regimen of direct anti HCV agents

作　　者：万佳亮 贺星[1] 白玫[1] 

机构地区：[1]天津药物研究院,天津300193

出　　处：《现代药物与临床》2014年第4期442-446,共5页Drugs & Clinic

摘　　要：全球丙肝病毒感染者已达到2亿人,而以干扰素为基础的标准治疗存在诸多不足,开发直接抗丙肝病毒药物成为最新的研究方向。但是这类药物单独使用或与干扰素联合使用时,病毒会产生耐药性。因此为了满足临床需求,很多直接抗丙肝药物的联合治疗方案正处于研究阶段,对目前在研的直接抗丙肝药物联合治疗方案的研究进展做以简要综述。The number of people who infected hepatitis C virus （HCV） has been more than 200 million all over the world. However, there are several drawbacks in the standard treatments of HCV based on interferon, thus the development of the direct anti HCV agents will be the frontier. Due to the resistance from the single use or the combination of direct anti HCV agents with interferon, researchers are ongoing to develop the combination treatments of two or more direct anti HCV agents without interferon. The development of the direct anti HCV agents combination therapy is reviewed in this paper.

关 键 词：直接抗病毒药物 丙肝病毒 联合治疗 干扰素 

分 类 号：R978.7[医药卫生—药品]